Tyra Biosciences, Inc. - TYRA
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Commodore Capital LP | 4.2% | 2,475,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Commodore Capital Master LP | 4.2% | 2,475,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Robert Egen Atkinson | 4.2% | 2,475,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Michael Kramarz | 4.2% | 2,475,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | JANUS HENDERSON GROUP PLC | 7.2% | 3,890,589 | View |
| May 14, 2026 | SCHEDULE 13G/A | Todd Harris | 4.8% | 2,913,342 | View |
| May 12, 2026 | SCHEDULE 13G/A | Farallon Capital Partners, L.P. | 1.1% | 579,376 | View |
| May 12, 2026 | SCHEDULE 13G/A | Farallon Capital Institutional Partners, L.P. | 1.4% | 739,107 | View |
| May 12, 2026 | SCHEDULE 13G/A | Farallon Capital Institutional Partners II, L.P. | 0.2% | 121,341 | View |
| May 12, 2026 | SCHEDULE 13G/A | Farallon Capital Institutional Partners III, L.P. | 0.2% | 105,941 | View |
| May 12, 2026 | SCHEDULE 13G/A | Four Crossings Institutional Partners V, L.P. | 0.2% | 126,343 | View |
| May 12, 2026 | SCHEDULE 13G/A | Farallon Capital Offshore Investors II, L.P. | 2.7% | 1,452,596 | View |
| May 12, 2026 | SCHEDULE 13G/A | Farallon Capital (AM) Investors, L.P. | 0.1% | 74,008 | View |
| May 12, 2026 | SCHEDULE 13G/A | Farallon Capital F5 Master I, L.P. | 0.3% | 173,106 | View |
| May 12, 2026 | SCHEDULE 13G/A | Farallon Healthcare Partners Master, L.P. | 0.4% | 209,000 | View |
| May 12, 2026 | SCHEDULE 13G/A | Farallon Partners, L.L.C. | 6.3% | 3,407,712 | View |
| May 12, 2026 | SCHEDULE 13G/A | Farallon Institutional (GP) V, L.L.C. | 0.2% | 126,343 | View |
| May 12, 2026 | SCHEDULE 13G/A | Farallon F5 (GP), L.L.C. | 0.3% | 173,106 | View |
| May 12, 2026 | SCHEDULE 13G/A | Farallon Healthcare Partners (GP), L.L.C. | 0.4% | 209,000 | View |
| May 12, 2026 | SCHEDULE 13G/A | Dapice Joshua J. | 6.6% | 3,580,818 | View |
| May 12, 2026 | SCHEDULE 13G/A | Dreyfuss, Philip D. | 6.6% | 3,580,818 | View |
| May 12, 2026 | SCHEDULE 13G/A | Dunn Hannah E. | 6.6% | 3,580,818 | View |
| May 12, 2026 | SCHEDULE 13G/A | Gehani, Varun N. | 6.6% | 3,580,818 | View |
| May 12, 2026 | SCHEDULE 13G/A | Giauque, Nicolas | 6.6% | 3,580,818 | View |
| May 12, 2026 | SCHEDULE 13G/A | Husen, Avner A. | 6.6% | 3,580,818 | View |
| May 12, 2026 | SCHEDULE 13G/A | Kim, David T. | 6.6% | 3,580,818 | View |
| May 12, 2026 | SCHEDULE 13G/A | Linn, Michael G. | 6.6% | 3,580,818 | View |
| May 12, 2026 | SCHEDULE 13G/A | Luo Patrick (Cheng) | 6.6% | 3,580,818 | View |
| May 12, 2026 | SCHEDULE 13G/A | Roberts, Jr., Thomas G. | 6.6% | 3,580,818 | View |
| May 12, 2026 | SCHEDULE 13G/A | Saito Edric C. | 6.6% | 3,580,818 | View |
| May 12, 2026 | SCHEDULE 13G/A | Short Daniel S. | 6.6% | 3,580,818 | View |
| May 12, 2026 | SCHEDULE 13G/A | Spokes, Andrew J. M. | 6.6% | 3,580,818 | View |
| May 12, 2026 | SCHEDULE 13G/A | Warren, John R. | 6.6% | 3,580,818 | View |
| May 12, 2026 | SCHEDULE 13G/A | Wehrly, Mark C. | 6.6% | 3,580,818 | View |
| Apr 24, 2026 | SCHEDULE 13G/A | Canaan XI L.P. | 1.4% | 750,000 | View |
| Apr 24, 2026 | SCHEDULE 13G/A | Canaan Partners XI LLC | 1.4% | 750,000 | View |
| Apr 24, 2026 | SCHEDULE 13G/A | Canaan 2020+ Co-Investment L.P. - Series 7 | 0.0% | 0 | View |
| Apr 24, 2026 | SCHEDULE 13G/A | Canaan Partners 2020+ Co-Investment LLC | 0.0% | 0 | View |
| Apr 07, 2026 | SCHEDULE 13G | FMR LLC | 14.4% | 7,747,648 | View |
| Apr 07, 2026 | SCHEDULE 13G | Abigail P. Johnson | 14.4% | 7,747,648 | View |
| Mar 06, 2026 | SCHEDULE 13D/A | — | 19.99% | — | View |
| Feb 20, 2026 | SCHEDULE 13G | Farallon Capital Partners, L.P. | 0.9% | 505,122 | View |
| Feb 20, 2026 | SCHEDULE 13G | Farallon Capital Institutional Partners, L.P. | 1.2% | 650,679 | View |
| Feb 20, 2026 | SCHEDULE 13G | Farallon Capital Institutional Partners II, L.P. | 0.2% | 120,651 | View |
| Feb 20, 2026 | SCHEDULE 13G | Farallon Capital Institutional Partners III, L.P. | 0.2% | 94,197 | View |
| Feb 20, 2026 | SCHEDULE 13G | Four Crossings Institutional Partners V, L.P. | 0.2% | 120,497 | View |
| Feb 20, 2026 | SCHEDULE 13G | Farallon Capital Offshore Investors II, L.P. | 2.4% | 1,272,095 | View |
| Feb 20, 2026 | SCHEDULE 13G | Farallon Capital (AM) Investors, L.P. | 0.1% | 65,624 | View |
| Feb 20, 2026 | SCHEDULE 13G | Farallon Capital F5 Master I, L.P. | 0.3% | 155,953 | View |
| Feb 20, 2026 | SCHEDULE 13G | Farallon Partners, L.L.C. | 5.3% | 2,828,865 | View |
| Feb 20, 2026 | SCHEDULE 13G | Farallon Institutional (GP) V, L.L.C. | 0.2% | 120,497 | View |
| Feb 20, 2026 | SCHEDULE 13G | Farallon F5 (GP), L.L.C. | 0.3% | 155,953 | View |
| Feb 20, 2026 | SCHEDULE 13G | Dapice Joshua J. | 5.6% | 2,984,818 | View |
| Feb 20, 2026 | SCHEDULE 13G | Dreyfuss, Philip D. | 5.6% | 2,984,818 | View |
| Feb 20, 2026 | SCHEDULE 13G | Dunn Hannah E. | 5.6% | 2,984,818 | View |
| Feb 20, 2026 | SCHEDULE 13G | Gehani, Varun N. | 5.6% | 2,984,818 | View |
| Feb 20, 2026 | SCHEDULE 13G | Giauque, Nicolas | 5.6% | 2,984,818 | View |
| Feb 20, 2026 | SCHEDULE 13G | Husen, Avner A. | 5.6% | 2,984,818 | View |
| Feb 20, 2026 | SCHEDULE 13G | Kim, David T. | 5.6% | 2,984,818 | View |
| Feb 20, 2026 | SCHEDULE 13G | Linn, Michael G. | 5.6% | 2,984,818 | View |
| Feb 20, 2026 | SCHEDULE 13G | Luo Patrick (Cheng) | 5.6% | 2,984,818 | View |
| Feb 20, 2026 | SCHEDULE 13G | Roberts, Jr., Thomas G. | 5.6% | 2,984,818 | View |
| Feb 20, 2026 | SCHEDULE 13G | Saito Edric C. | 5.6% | 2,984,818 | View |
| Feb 20, 2026 | SCHEDULE 13G | Short Daniel S. | 5.6% | 2,984,818 | View |
| Feb 20, 2026 | SCHEDULE 13G | Spokes, Andrew J. M. | 5.6% | 2,984,818 | View |
| Feb 20, 2026 | SCHEDULE 13G | Warren, John R. | 5.6% | 2,984,818 | View |
| Feb 20, 2026 | SCHEDULE 13G | Wehrly, Mark C. | 5.6% | 2,984,818 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 2.1% | 1,135,053 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 2.1% | 1,135,053 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 1.6% | 829,908 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 1.6% | 829,908 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.2% | 130,502 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.2% | 130,502 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 3.7% | 1,964,961 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 4.0% | 2,127,665 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF INC/IL | 4.0% | 2,127,665 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 4.0% | 2,127,665 | View |
| Feb 13, 2026 | SCHEDULE 13G | Todd Harris | 5.1% | 2,814,379 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Canaan XI L.P. | 5.5% | 2,930,444 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Canaan Partners XI LLC | 5.5% | 2,930,444 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Canaan 2020+ Co-Investment L.P. - Series 7 | 0.8% | 443,885 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Canaan Partners 2020+ Co-Investment LLC | 0.8% | 443,885 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.